Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial
Cannabigerol (CBG) may be a promising option for reducing anxiety and stress in healthy adults without causing impairment or significant side effects.
Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ 9 ‐Tetrahydrocannabinol Without Improving Its Analgesic Properties
Clinicians should be aware that while CBD may increase the psychoactive effects of THC, it does not enhance its analgesic properties.
Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?
Sublingual THC:CBD oil extracts administered at modest, individually titrated daily doses (around 20 mg each) provided statistically significant.
A remote brief intervention plus social media messaging for cannabis use among emerging adults: A pilot randomized controlled trial in emergency department patients
Combining a brief motivational interviewing session with 4 weeks of tailored health coaching via a familiar social media platform (Snapchat) is a highly.
Cannabinoid therapeutics in orofacial pain management: a systematic review
While current systemic and oral cannabinoid formulations lack robust evidence for managing acute orofacial and post-operative dental pain.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality.
Administering 20 mg of isolated cannabinol (CBN) nightly can effectively reduce nighttime awakenings and overall sleep disturbance in patients with.
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study
Consider recommending CBD-dominant cannabis for patients with anxiety symptoms, as it may provide greater relief compared to THC-dominant options.
A Preliminary Pharmacokinetic Comparison of Δ-9 Tetrahydrocannabinol and Cannabidiol Extract Versus Oromucosal Spray in Healthy Men and Women
Clinicians should consider the route of administration when prescribing THC:CBD formulations, as bioavailability may vary significantly between methods.
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report
Clinicians should be aware of the potential driving impairments associated with cannabis use and advise patients accordingly.
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model
In this double-blind laboratory study, low-dose oral cannabidiol (50 mg) enhanced the acute analgesic properties of 4 mg hydromorphone without increasing.
